Flex Pharma to Report Second Quarter 2017 Results on August 2, 2017
Click to Tweet
Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and
proprietary treatments for cramps and spasticity associated with serious neurological diseases including amyotrophic lateral
sclerosis (ALS), multiple sclerosis (MS), and Charcot-Marie-Tooth (CMT), announced today that it will report its financial results
for the second quarter ended June 30, 2017 on Wednesday, August 2, 2017 before the U.S. financial markets open. The Company will
host a conference call and webcast at 8:45 a.m. ET to discuss second quarter 2017 financial results and provide a business update.
Individuals interested in participating in the call should dial (855) 780-7202 (U.S. and Canada) or (631) 485-4874
(International).
A live webcast may be accessed in the Investors section of the Company's website at www.flex-pharma.com. Please log on to the Flex Pharma website approximately 15 minutes prior to the scheduled
webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Flex
Pharma's website for three months.
About Flex Pharma
Flex Pharma, Inc. is a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps
and spasticity associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth
(CMT). Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean,
Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chair Christoph Westphal, M.D., Ph.D.
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
SVP, Investor Relations & Corporate Communications
irdept@flex-pharma.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170726005099/en/